FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2795010050> ?p ?o ?g. }

• W2795010050 abstract "Some Chinese patients with esophageal squamous cell carcinomaare often treated with single-agent concurrent chemoradiotherapy. However, no results have been reported from randomized controlled clinical trials comparing single-agent with double-agent concurrent chemoradiotherapy. It therefore remains unclear whether these regimens are equally clinically effective. In this study, we retrospectively analyzed and compared the therapeutic effects of single-agent and double-agent concurrent chemoradiotherapy in patients with unresectable esophageal squamous cell carcinoma.This study enrolled 168 patients who received definitive concurrent chemoradiotherapy for locally advanced unresectable esophageal squamous carcinoma at 10 hospitals between 2010 and 2015. We evaluated survival time and toxicity. The Kaplan-Meier method was used to estimate survival data. The log-rank test was used in univariate analysis A Cox proportional hazards regression model was used to conduct a multivariate analysis of the effects of prognostic factors on survival.In this study, 100 (59.5%) and 68 patients (40.5%) received single-agent and dual-agent combination chemoradiotherapy, respectively. The estimate 5-year progression-free survival (PFS) rate and overall survival (OS) rate of dual-agent therapy was higher than that of single-agent therapy (52.5% and 40.9%, 78.2% and 60.7%, respectively), but there were no significant differences (P = 0.367 and 0.161, respectively). Multivariate analysis showed that sex, age,and radiotherapy dose had no significant effects on OS or PFS. Only disease stage was associated with OS and PFS in the multivariable analysis (P = 0.006 and 0.003, respectively). In dual-agent group, the incidence of acute toxicity and the incidence of 3 and4 grade toxicity were higher than single-agent group.The 5-year PFS and OS rates of dual-agent therapy were higher than those of single-agent concurrent chemoradiotherapy for patients with unresectable esophageal squamous cell carcinoma; however, there were no significant differences in univariate analysis and multivariable analysis. Single-agent concurrent chemotherapy had less toxicity than a double-drug regimen. Therefore, we suggest that single therapis not inferior to dual therapy y. In the future, we aim to confirm our hypothesis through a prospective randomized study." @default.
• W2795010050 created "2018-04-06" @default.
• W2795010050 creator A5011520700 @default.
• W2795010050 creator A5017631853 @default.
• W2795010050 creator A5018612055 @default.
• W2795010050 creator A5019377130 @default.
• W2795010050 creator A5043220997 @default.
• W2795010050 creator A5045704541 @default.
• W2795010050 creator A5047125848 @default.
• W2795010050 creator A5049006834 @default.
• W2795010050 creator A5061645783 @default.
• W2795010050 creator A5065918130 @default.
• W2795010050 creator A5069972187 @default.
• W2795010050 creator A5073681533 @default.
• W2795010050 creator A5087279946 @default.
• W2795010050 date "2018-01-22" @default.
• W2795010050 modified "2023-10-16" @default.
• W2795010050 title "Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis" @default.
• W2795010050 cites W1803553840 @default.
• W2795010050 cites W1946726115 @default.
• W2795010050 cites W1957194715 @default.
• W2795010050 cites W1980360320 @default.
• W2795010050 cites W2035266336 @default.
• W2795010050 cites W2087149654 @default.
• W2795010050 cites W2091145532 @default.
• W2795010050 cites W2096656641 @default.
• W2795010050 cites W2104360894 @default.
• W2795010050 cites W2114276360 @default.
• W2795010050 cites W2116964952 @default.
• W2795010050 cites W2117223681 @default.
• W2795010050 cites W2119696360 @default.
• W2795010050 cites W2128559738 @default.
• W2795010050 cites W2140625837 @default.
• W2795010050 cites W2144263975 @default.
• W2795010050 cites W2146269511 @default.
• W2795010050 cites W2148421421 @default.
• W2795010050 cites W2148426014 @default.
• W2795010050 cites W2164986334 @default.
• W2795010050 cites W2279592974 @default.
• W2795010050 cites W2295530670 @default.
• W2795010050 cites W2333224485 @default.
• W2795010050 cites W2333908381 @default.
• W2795010050 cites W2917837889 @default.
• W2795010050 cites W4211048478 @default.
• W2795010050 cites W4236554935 @default.
• W2795010050 doi "https://doi.org/10.1186/s13014-018-0958-5" @default.
• W2795010050 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5778746" @default.
• W2795010050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29357883" @default.
• W2795010050 hasPublicationYear "2018" @default.
• W2795010050 type Work @default.
• W2795010050 sameAs 2795010050 @default.
• W2795010050 citedByCount "6" @default.
• W2795010050 countsByYear W27950100502019 @default.
• W2795010050 countsByYear W27950100502020 @default.
• W2795010050 countsByYear W27950100502021 @default.
• W2795010050 countsByYear W27950100502022 @default.
• W2795010050 crossrefType "journal-article" @default.
• W2795010050 hasAuthorship W2795010050A5011520700 @default.
• W2795010050 hasAuthorship W2795010050A5017631853 @default.
• W2795010050 hasAuthorship W2795010050A5018612055 @default.
• W2795010050 hasAuthorship W2795010050A5019377130 @default.
• W2795010050 hasAuthorship W2795010050A5043220997 @default.
• W2795010050 hasAuthorship W2795010050A5045704541 @default.
• W2795010050 hasAuthorship W2795010050A5047125848 @default.
• W2795010050 hasAuthorship W2795010050A5049006834 @default.
• W2795010050 hasAuthorship W2795010050A5061645783 @default.
• W2795010050 hasAuthorship W2795010050A5065918130 @default.
• W2795010050 hasAuthorship W2795010050A5069972187 @default.
• W2795010050 hasAuthorship W2795010050A5073681533 @default.
• W2795010050 hasAuthorship W2795010050A5087279946 @default.
• W2795010050 hasBestOaLocation W27950100501 @default.
• W2795010050 hasConcept C10515644 @default.
• W2795010050 hasConcept C121608353 @default.
• W2795010050 hasConcept C126322002 @default.
• W2795010050 hasConcept C143998085 @default.
• W2795010050 hasConcept C144301174 @default.
• W2795010050 hasConcept C146357865 @default.
• W2795010050 hasConcept C151730666 @default.
• W2795010050 hasConcept C2778424827 @default.
• W2795010050 hasConcept C2779742542 @default.
• W2795010050 hasConcept C38180746 @default.
• W2795010050 hasConcept C50382708 @default.
• W2795010050 hasConcept C509974204 @default.
• W2795010050 hasConcept C71924100 @default.
• W2795010050 hasConcept C86803240 @default.
• W2795010050 hasConceptScore W2795010050C10515644 @default.
• W2795010050 hasConceptScore W2795010050C121608353 @default.
• W2795010050 hasConceptScore W2795010050C126322002 @default.
• W2795010050 hasConceptScore W2795010050C143998085 @default.
• W2795010050 hasConceptScore W2795010050C144301174 @default.
• W2795010050 hasConceptScore W2795010050C146357865 @default.
• W2795010050 hasConceptScore W2795010050C151730666 @default.
• W2795010050 hasConceptScore W2795010050C2778424827 @default.
• W2795010050 hasConceptScore W2795010050C2779742542 @default.
• W2795010050 hasConceptScore W2795010050C38180746 @default.
• W2795010050 hasConceptScore W2795010050C50382708 @default.
• W2795010050 hasConceptScore W2795010050C509974204 @default.
• W2795010050 hasConceptScore W2795010050C71924100 @default.
• W2795010050 hasConceptScore W2795010050C86803240 @default.
• W2795010050 hasLocation W27950100501 @default.

• next